Table 3 Associations of miR-20a-5p expression levels with breast cancer risk factors.

From: Roles of miR-20a-5p in breast cancer based on the clinical and multi-omic (CAMO) cohort and in vitro studies

 

Stroma

Cytoplasm

Nucleus

Cytoplasm and nucleus

High

Low

High

Low

High

Low

High/high

Low/low

Mixed

Age at diagnosis, y, median (IQR)

52 (14)

57 (9)

54 (13)

57 (8)

56 (13)

57 (7)

54 (16)

57 (7)

57 (11)

 p

0.009*

0.049*

0.49

0.15

BMI, n (%)

 < 25

31 (68.9)

149 (58.0)

46 (63.0)

135 (58.2)

116 (65.5)

65 (50.8)

45 (63.4)

64 (50.8)

72 (66.7)

 25–30

12 (26.7)

82 (31.9)

22 (30.1)

73 (31.5)

46 (26.0)

49 (38.3)

21 (29.6)

48 (38.1)

26 (24.1)

 > 30

2 (4.4)

26 (10.1)

5 (6.0)

24 (10.3)

15 (8.5)

14 (10.9)

5 (7.0)

14 (11.8)

10 (9.3)

 p

0.30

0.62

0.033*

0.12

Age at menarche, y, mean (SD)

12.9 (1.1)

13.5 (1.4)

13.1 (1.3)

13.0 (1.3)

13.0 (1.3)

13.1 (1.3)

13.0 (1.3)

13.1 (1.3)

12.9 (1.3)

 p

0.26

 

0.60

 

0.19

 

0.99

  

Menopausal status**, n (%)

 Post

23 (50.0)

194 (73.8)

43 (58.9)

176 (73.6)

119 (66.1)

100 (75.8)

41 (57.8)

98 (75.4)

80 (72.1)

 Pre

23 (50.0)

69 (26.2)

30 (41.1)

63 (26.4)

61 (33.9)

32 (24.2)

30 (42.3)

32 (24.6)

31 (27.9)

 p

0.001*

 

0.016*

 

0.07

 

0.028*

  

Parity, n (%)

 Parous

42 (91.3)

236 (89.7)

68 (93.2)

212 (88.7)

160 (88.9)

120 (90.9)

66 (93.0)

118 (90.8)

96 (86.5)

 Nulliparous

4 (8.7)

27 (10.3)

5 (6.9)

27 (11.3)

20 (11.1)

12 (9.1)

5 (7.0)

12 (9.2)

15 (13.5)

 p

0.74

 

0.27

 

0.56

 

0.33

  

OC use, n (%)

 Yes

25 (55.6)

159 (62.9)

44 (62.0)

142 (61.7)

111 (63.4)

75 (59.5)

43 (62.3)

74 (59.7)

69 (63.9)

 No

20 (44.4)

94 (37.2)

27 (38.0)

88 (38.3)

64 (36.6)

51 (40.5)

26 (37.7)

50 (40.3)

39 (36.1)

 p

0.35

 

0.97

 

0.49

 

0.80

  

Alcohol consumption, g, median (IQR)

2.1 (2.4)

1.6 (4.7)

2.1 (2.7)

1.6 (4.1)

1.7 (3.5)

1.6 (5.0)

2.1 (2.7)

1.6 (5.1)

1.5 (3.1)

 p

0.88

 

0.18

 

0.39

 

0.15

  

Smoking, n (%)

 Never

14 (30.4)

92 (35.1)

24 (32.9)

84 (35.3)

65 (36.1)

43 (32.8)

24 (33.8)

43 (33.3)

41 (36.9)

 Ever

32 (69.6)

170 (64.9)

49 (67.1)

154 (64.7)

115 (63.9)

88 (67.2)

47 (66.2)

86 (66.7)

70 (63.1)

 p

0.54

 

0.70

 

0.55

 

0.83

  

Mother with BC, n (%)

 Yes

1 (2.2)

13 (5.3)

5 (7.1)

9 (4.0)

9 (5.3)

5 (4.0)

5 (7.4)

5. (4.1)

4 (3.8)

 No

44 (97.8)

234 (94.7)

65 (92.9)

216 (96.0)

162 (94.7)

119 (96.0)

63 (92.7)

117 (95.9)

101 (96.2)

 p

0.38

 

0.28

 

0.62

 

0.51

  

Sister with BC, n (%)

 Yes

1 (2.4)

4 (1.8)

1 (1.6)

4 (2.0)

4 (2.6)

1 (0.9)

1 (1.7)

1 (0.9)

3 (3.2)

 No

40 (97.6)

218 (98.2)

60 (98.4)

201 (98.1)

148 (97.4)

113 (99.1)

58 (98.3)

111 (99.1)

92 (96.8)

 p

0.78

 

0.88

 

0.30

 

0.49

  
  1. Associations between breast cancer risk factors and miR-20a-5p expression in tumor stromal fibroblasts (stroma), cancer cell cytoplasm (cytoplasm), cancer cell nuclei (nucleus), and cancer cell compartments combined. BC breast cancer, BMI body mass index, g grams, IQR interquartile range, OC oral contraceptive, SD standard deviation, y years. *Statistically significant (p < 0.05). **Menopausal status at diagnosis.